NAD+: Identity, Human Evidence, and FDA Status

NAD+ is the oxidized form of nicotinamide adenine dinucleotide, a coenzyme involved in cellular redox reactions and used as a substrate by several enzyme systems. It is not a peptide.

The molecule’s essential biochemical role does not prove that direct exposure to an NAD+ product improves energy, mitochondrial function, DNA repair, wellness, or longevity in people. Direct human studies remain limited, current trial records have important gaps, and human measurements do not support the universal claim that blood NAD+ always declines with age.

This page separates molecule-level biology, direct human research, FDA compounding status, and commercial-sample identity. It does not provide medical advice or use instructions, and it does not validate either Serum Research NAD+ item.

Evidence state at a glance

What exactly is NAD+?

FDA’s substance database uses nadide as the preferred name for the beta form commonly called NAD+.[1] The same record supplies the formula, molecular weight, stereochemical definition, CAS number, and UNII. PubChem maintains a corresponding beta-nicotinamide adenine dinucleotide structure record.[2]

NAD+ is the oxidized member of the NAD+/NADH redox pair. NADH is the reduced form. The two names are not interchangeable.

A physical material also needs more detail than “NAD+.” It may be represented as an inner-salt/free form, a sodium salt, a hydrate, or another preparation. Those differences change formula, molecular weight, reference standards, and how a labeled milligram amount is interpreted.

What does NAD+ do in cells?

NAD+ accepts and transfers electrons in many redox reactions. Cells also consume it in reactions involving enzyme families such as sirtuins and poly(ADP-ribose) polymerases. Reactome’s reviewed human pathway maps several routes that synthesize and regenerate NAD+.[3]

This is strong evidence for a central biochemical role. It does not establish that an external NAD+ material reaches a particular tissue, changes a clinical endpoint, or produces an anti-aging effect.

The distinction is similar to many essential molecules: biological importance is not the same as evidence for a product outcome.

Synthesis and transport are different processes

Experiments identifying SLC25A51 provide a particularly useful example. The 2020 primary report found that reducing this transporter lowered mitochondrial NAD+ and impaired respiration without comparably lowering whole-cell NAD+. Uptake into isolated mitochondria was impaired; complementary expression experiments supported transport activity. These are cellular and organelle experiments establishing a transport mechanism. SLC25A51 primary study

The result corrects the overly broad statement that intact NAD+ can never cross any mammalian membrane. It does not establish that externally administered NAD+ crosses the plasma membrane of every tissue, survives extracellular metabolism intact, or reaches human brain mitochondria. The mitochondrial membrane and the boundary between the bloodstream and a tissue cell are different barriers.

What has direct human NAD+ research shown?

Eleven healthy men participated: eight received NAD+ and three received saline. The Methods report randomized allocation, although sequence generation, concealment and masking are not described. Sampling extended through eight hours, with no statistically significant early plasma increase and later changes in NAD+ and selected metabolites. Grant and colleagues primary report

Calling the study nonrandomized would contradict its Methods. Calling it a definitive randomized efficacy trial would misrepresent its objective and reporting. Random allocation is one design feature; it does not turn chemical measurements into clinical outcomes or remove uncertainty from a three-person control group.

Two current ClinicalTrials.gov records add context but not conclusions:

• NCT06382688 compared nicotinamide riboside with direct NAD+. Its registry status was unknown, enrollment was 53, and no results were posted when checked for this page.[6]

• The trial registry places study completion in June 2022 and first public posting in January 2026, so registration was retrospective. As checked October 6, 2026, the registry had no posted results, although the peer-reviewed paper was available. “No registry results” therefore must not be rewritten as “no published results.” NCT07336836 registry

A registered or completed study with no posted results cannot support an effectiveness claim. Studies of NAD+ precursors also should not be presented as if they tested direct NAD+.

What the two trials support

The 2024 study enrolled 60 patients and analyzed 58, with 29 in each group. It reported randomized, double-blind allocation to NAD+ or saline. Between-group comparisons of improvement rates in NT-proBNP and left-ventricular ejection fraction were not significant at the reported visits. A separate NT-proBNP trajectory analysis and some other biomarker analyses differed between groups. One-year clinical comparisons were not significant. Primary report and Tables 2 to 5

A later single-center study randomized 180 adults with ischemic cardiomyopathy. The report found a favorable one-month ejection-fraction comparison, but six-month composite cardiac and cerebrovascular events and first unplanned heart-failure hospitalization did not reach statistical significance. Functional-class and several other comparisons also remained uncertain. 2025 primary report

The cardiac literature supplies a reason for further condition-specific research, not a general anti-aging conclusion. Patients receiving background treatment in a monitored trial differ from healthy commercial clients in baseline disease, concomitant care and outcome priorities. Treatment timing, formulation and follow-up also define the comparison.

Does NAD+ always decline with age?

No universal human conclusion is justified. Measurements vary by tissue, sample handling, assay, cohort, sex, and other study choices.

A 2026 study used a validated mass-spectrometry method across seven independent human cohorts. It reported that whole-blood NAD+ remained stable with age and across the lifestyle interventions examined.[5] That primary finding directly challenges simple claims that everyone’s blood NAD+ falls as they get older.

NAD+ remains relevant to aging biology. The evidence-safe statement is that human age associations are inconsistent and do not prove that direct NAD+ exposure changes aging outcomes.

Current FDA context

FDA’s May 14, 2026 compounding document places “Nicotinamide Adenine Dinucleotide (NAD)” in 503A Category 1, which means the nominated substance is under evaluation. It separately places “Beta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate” in Category 3, for nominations without adequate support for evaluation.[8]

Neither category is FDA approval.

FDA has also warned compounders about food-grade NAD+ being used in products expected to be sterile. The agency described contamination and endotoxin concerns and adverse-event reports involving NAD+ injectable drugs.[9] In a January 2026 warning letter, FDA said NAD+ used by the inspected outsourcing facility was not eligible for 503B exemptions under the circumstances described.[10]

These records concern compounding eligibility and quality risk. They are not findings about a Serum Research lot, but they show why ingredient grade and microbiological evidence cannot be assumed from a molecule name.

A specific investigated cluster

FDA's January 20, 2026 warning letter to GenoGenix describes three patients developing symptoms after receiving a product containing NAD+ from the same vial. Symptoms included low blood pressure, shaking, shivers and body aches. An unopened vial from the same lot subsequently tested at 3360 EU/mL of bacterial endotoxins. The letter also describes release without finished-product testing. FDA GenoGenix letter

The combination of a shared exposure and analytical evidence is more specific than a narrative symptom report alone. It still concerns the identified manufacturer's product and lot. Nothing in that letter attributes the cluster to Serum Research, and it would be misleading to transfer the finding to an unrelated supplier.

Conversely, the absence of such a finding about another supplier is not independent evidence that its material meets a clinical standard. That question requires evidence about the actual preparation and its manufacture.

Why the catalog products are not linked

The public Serum Research catalog has two NAD+ records. One URL says 200 mg while its title and body say 6,000 mg. The other says 500 mg but does not publicly identify the salt or hydrate, molecular-weight basis, reference standard, or matching lot evidence.

Before either item can be linked, the physical label and inventory record must establish:

• the correct total amount and units;
• beta-NAD+/nadide identity and stereochemical specification;
• salt, hydrate, formula, and molecular weight;
• whether the displayed mass is total material or active-moiety equivalent;
• quantitative content, impurities, and stability evidence for the matching lot;
• support for any grade, purity, testing, or manufacturing claim.

A substance database, trial paper, or generic certificate cannot fill those product-specific gaps.

Major evidence limitations

• NAD+ has an established biochemical role, but direct human outcome evidence is limited.
• The small human pilot described metabolite behavior, not clinical effectiveness.
• Highlighted current trial records had no posted results at the review date.
• Human age-association findings are inconsistent; a 2026 seven-cohort study found stable whole-blood NAD+ with age.
• Evidence about nicotinamide riboside, nicotinamide mononucleotide, or NADH is not direct NAD+ evidence.
• FDA 503A Category 1 status is not approval.
• A molecule name and vial amount do not establish form, content, impurities, stability, sterility, or equivalence to study material.

Frequently asked questions

Is NAD+ a peptide?

No. NAD+ is a dinucleotide coenzyme, not an amino-acid chain.

Are NAD+ and NADH the same?

No. They are the oxidized and reduced members of a redox pair. A product identity record should state which substance it contains.

Does cellular NAD+ biology prove an energy or longevity benefit?

No. A central biochemical role does not establish a clinical outcome from direct exposure to an external product.

Does NAD+ always decrease with age?

The human record is inconsistent. A 2026 analysis across seven cohorts found whole-blood NAD+ stable with age.[5]

Is NAD+ FDA approved?

No FDA-approved finished NAD+ drug was identified in the Drugs@FDA/Orange Book search for this review. FDA’s compounding-category and substance-identity records do not constitute approval.[1][8][11]

Does this page validate either Serum Research NAD+ product?

No. Both links remain blocked until the amount, form, mass basis, and matching lot evidence are reconciled.

Primary and official sources

1. FDA GSRS/UNII record for NADIDE, 0U46U6E8UK
2. PubChem beta-nicotinamide adenine dinucleotide, CID 925
3. Reactome reviewed human nicotinate-metabolism pathway
4. Direct NAD+ human metabolome pilot, PMID 31572171
5. Seven-cohort human whole-blood NAD+ study, PMID 42135539
6. ClinicalTrials.gov NCT06382688
7. ClinicalTrials.gov NCT07336836
8. FDA 503A bulk-substance categories, updated May 14, 2026
9. FDA reminder on ingredients suitable for sterile compounding
10. FDA warning letter to GenoGenix LLC, January 20, 2026
11. FDA explanation of Drugs@FDA coverage

Internal links after publication: Research Library hub; How We Review Evidence; Approved Drug vs Research Material; Quality Testing. Do not link either NAD+ product while the amount, form, and lot-document gates remain open.